EGLN2 and acute myeloid leukemia: We demonstrate that genetic inactivation of PHD1 and PHD2 compromises both AML initiation, disease progression, hinders leukemic stem cell (LSC) maintenance, but has no significant impact on multilineage hematopoiesis.